AstraZeneca (LON:AZN) Receives “Buy” Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Berenberg Bank in a research report issued on Thursday, Digital Look reports. They currently have a £160 price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price objective would indicate a potential upside of 32.61% from the company’s current price.

Several other research analysts have also recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Wednesday. Citigroup lifted their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Monday, August 3rd. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of £152.17.

AstraZeneca Stock Performance

AZN stock opened at £120.66 on Thursday. The stock’s 50 day simple moving average is £126.49 and its 200 day simple moving average is £137.02. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The stock has a market capitalization of £187.13 billion, a PE ratio of 18.06, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.